Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 5/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.54 |
| ▸ | REN | P00797 | 6/20 | 0.50 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.47 |
| ▸ | EED | O75530 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23331247 | 0.97 | KISS1R (0.55) | KISS1ROPRK1RENPSEN1PSEN2 | |
| SCHEMBL23331151 | 0.92 | KISS1R (0.51) | KISS1ROPRK1 | |
| SCHEMBL23331567 | 0.91 | CTSD (0.50) | KISS1ROPRK1 | |
| SCHEMBL23330996 | 0.90 | KISS1R (0.51) | KISS1ROPRK1REN | |
| SCHEMBL23330903 | 0.90 | KISS1R (0.51) | KISS1ROPRK1REN | |
| SCHEMBL23331150 | 0.89 | KISS1R (0.49) | KISS1ROPRK1 | |
| SCHEMBL23331575 | 0.88 | KISS1R (0.48) | KISS1ROPRK1 | |
| SCHEMBL23331248 | 0.84 | OPRD1 (0.53) | KISS1ROPRK1RENPSEN1PSEN2 | |
| SCHEMBL30439495 | 0.81 | NPY1R (0.54) | OPRK1 | |
| SCHEMBL29775538 | 0.81 | NPY1R (0.54) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364275-B2 | Linear lipopeptide paenipeptins and methods of using the same | BIOVENTURES, LLC (US) | 2022-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11364275-B2 | Linear lipopeptide paenipeptins and methods of using the same | NGLY1, VIP, CLPTM1 | KISS1R 1143/4885OPRK1 3994/4885REN 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.